Literature DB >> 24595818

The mixture of "ecstasy" and its metabolites impairs mitochondrial fusion/fission equilibrium and trafficking in hippocampal neurons, at in vivo relevant concentrations.

Daniel José Barbosa1, Romàn Serrat, Serena Mirra, Martí Quevedo, Elena Goméz de Barreda, Jesús Àvila, Luísa Maria Ferreira, Paula Sério Branco, Eduarda Fernandes, Maria de Lourdes Bastos, João Paulo Capela, Eduardo Soriano, Félix Carvalho.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a potentially neurotoxic recreational drug of abuse. Though the mechanisms involved are still not completely understood, formation of reactive metabolites and mitochondrial dysfunction contribute to MDMA-related neurotoxicity. Neuronal mitochondrial trafficking, and their targeting to synapses, is essential for proper neuronal function and survival, rendering neurons particularly vulnerable to mitochondrial dysfunction. Indeed, MDMA-associated disruption of Ca(2+) homeostasis and ATP depletion have been described in neurons, thus suggesting possible MDMA interference on mitochondrial dynamics. In this study, we performed real-time functional experiments of mitochondrial trafficking to explore the role of in situ mitochondrial dysfunction in MDMA's neurotoxic actions. We show that the mixture of MDMA and six of its major in vivo metabolites, each compound at 10μM, impaired mitochondrial trafficking and increased the fragmentation of axonal mitochondria in cultured hippocampal neurons. Furthermore, the overexpression of mitofusin 2 (Mfn2) or dynamin-related protein 1 (Drp1) K38A constructs almost completely rescued the trafficking deficits caused by this mixture. Finally, in hippocampal neurons overexpressing a Mfn2 mutant, Mfn2 R94Q, with impaired fusion and transport properties, it was confirmed that a dysregulation of mitochondrial fission/fusion events greatly contributed to the reported trafficking phenotype. In conclusion, our study demonstrated, for the first time, that the mixture of MDMA and its metabolites, at concentrations relevant to the in vivo scenario, impaired mitochondrial trafficking and increased mitochondrial fragmentation in hippocampal neurons, thus providing a new insight in the context of "ecstasy"-induced neuronal injury.

Entities:  

Keywords:  3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”); MDMA's metabolites; mitochondrial dysfunction; mitochondrial fusion/fission; mitochondrial trafficking; neurotoxicity

Mesh:

Substances:

Year:  2014        PMID: 24595818     DOI: 10.1093/toxsci/kfu042

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  6 in total

Review 1.  Mitochondrial fusion, fission, and mitochondrial toxicity.

Authors:  Joel N Meyer; Tess C Leuthner; Anthony L Luz
Journal:  Toxicology       Date:  2017-08-05       Impact factor: 4.221

Review 2.  Metabolic Regulation of Glia and Their Neuroinflammatory Role in Alzheimer's Disease.

Authors:  Kumari Preeti; Anika Sood; Valencia Fernandes
Journal:  Cell Mol Neurobiol       Date:  2021-09-13       Impact factor: 4.231

3.  A review on the mitochondrial toxicity of "ecstasy" (3,4-methylenedioxymethamphetamine, MDMA).

Authors:  João Paulo Capela; Félix Dias Carvalho
Journal:  Curr Res Toxicol       Date:  2022-05-19

4.  Analysis of Statistical Methods Currently used in Toxicology Journals.

Authors:  Jihye Na; Hyeri Yang; SeungJin Bae; Kyung-Min Lim
Journal:  Toxicol Res       Date:  2014-09

Review 5.  Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration.

Authors:  María J Pérez; Claudia Jara; Rodrigo A Quintanilla
Journal:  Front Neurosci       Date:  2018-07-05       Impact factor: 4.677

6.  "Ecstasy" toxicity to adolescent rats following an acute low binge dose.

Authors:  Armanda Teixeira-Gomes; Vera Marisa Costa; Rita Feio-Azevedo; José Alberto Duarte; Margarida Duarte-Araújo; Eduarda Fernandes; Maria de Lourdes Bastos; Félix Carvalho; João Paulo Capela
Journal:  BMC Pharmacol Toxicol       Date:  2016-06-28       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.